ID   NC-37
AC   CVCL_3042
SY   NC 37; NC37; Nc37
DR   BTO; BTO:0005495
DR   CLO; CLO_0007952
DR   EFO; EFO_0002247
DR   CLDB; cl3648
DR   CLDB; cl3649
DR   ArrayExpress; E-MTAB-38
DR   ATCC; CCL-214
DR   BioSample; SAMN03151899
DR   BioSample; SAMN03471475
DR   cancercelllines; CVCL_3042
DR   Cell_Model_Passport; SIDM01207
DR   ChEMBL-Cells; CHEMBL3307322
DR   ChEMBL-Targets; CHEMBL614189
DR   Cosmic; 687848
DR   ECACC; 89111414
DR   HIVReagentProgram; ARP-9936
DR   IGRhCellID; NC37
DR   JCRB; IFO50039
DR   KCLB; 10214
DR   LINCS_LDP; LCL-2057
DR   NCBI_Iran; C501
DR   NCI-DTP; NC-37
DR   Progenetix; CVCL_3042
DR   PubChem_Cell_line; CVCL_3042
DR   RCB; RCB3008
DR   TKG; TKG 0232
DR   Wikidata; Q54907589
RX   PubMed=165156;
RX   PubMed=170370;
RX   PubMed=375235;
RX   PubMed=4321017;
RX   PubMed=4366935;
RX   PubMed=6401685;
RX   PubMed=6500159;
RX   PubMed=20143388;
RX   PubMed=20215515;
RX   PubMed=29892436;
WW   https://cellbank.nibiohn.go.jp/legacy/cellbank/qualitycontrol/identification/summary.htm
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a Raji derivative (PubMed=20143388). Originally thought to originate from the peripheral blood of a human donor not suffering from a disease.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00330.
CC   Population: African; Nigerian.
CC   Doubling time: ~20 hours (HIVReagentProgram=ARP-9936).
CC   Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: SNP array analysis.
CC   Discontinued: ECACC; 89111414; true.
CC   Discontinued: KCLB; 10214; probable.
CC   Derived from site: In situ; Bone, jaw, maxilla; UBERON=UBERON_0002397.
ST   Source(s): ATCC; JCRB; TKG
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 13 (JCRB; TKG)
ST   D13S317: 13,14 (ATCC)
ST   D16S539: 8,11
ST   D5S818: 10,13
ST   D7S820: 10
ST   TH01: 6,7
ST   TPOX: 8,13
ST   vWA: 16 (ATCC)
ST   vWA: 16,19 (JCRB; TKG)
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0511 ! Raji
SX   Male
AG   11Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 32
//
RX   PubMed=165156; DOI=10.1002/ijc.2910150217;
RA   Nilsson K., Ponten J.;
RT   "Classification and biological nature of established human
RT   hematopoietic cell lines.";
RL   Int. J. Cancer 15:321-341(1975).
//
RX   PubMed=170370; DOI=10.1099/0022-1317-28-2-207;
RA   Adams A., Strander H., Cantell K.;
RT   "Sensitivity of the Epstein-Barr virus transformed human lymphoid cell
RT   lines to interferon.";
RL   J. Gen. Virol. 28:207-217(1975).
//
RX   PubMed=375235; DOI=10.1073/pnas.76.3.1288;
RA   Sherwin S.A., Sliski A.H., Todaro G.J.;
RT   "Human melanoma cells have both nerve growth factor and nerve growth
RT   factor-specific receptors on their cell surfaces.";
RL   Proc. Natl. Acad. Sci. U.S.A. 76:1288-1292(1979).
//
RX   PubMed=4321017; DOI=10.1002/ijc.2910060315;
RA   Durr F.E., Monroe J.H., Schmitter R., Traul K.A., Hirshaut Y.;
RT   "Studies on the infectivity and cytopathology of Epstein-Barr virus in
RT   human lymphoblastoid cells.";
RL   Int. J. Cancer 6:436-449(1970).
//
RX   PubMed=4366935;
RA   Minowada J., Nonoyama M., Moore G.E., Rauch A.M., Pagano J.S.;
RT   "The presence of the Epstein-Barr viral genome in human lymphoblastoid
RT   B-cell lines and its absence in a myeloma cell line.";
RL   Cancer Res. 34:1898-1903(1974).
//
RX   PubMed=6401685; DOI=10.1007/BF02617989;
RA   Halton D.M., Peterson W.D. Jr., Hukku B.;
RT   "Cell culture quality control by rapid isoenzymatic
RT   characterization.";
RL   In Vitro 19:16-24(1983).
//
RX   PubMed=6500159; DOI=10.1159/000163283;
RA   Gershwin M.E., Lentz D., Owens R.B.;
RT   "Relationship between karyotype of tissue culture lines and
RT   tumorigenicity in nude mice.";
RL   Exp. Cell Biol. 52:361-370(1984).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=29892436; DOI=10.1098/rsos.172472;
RA   Shioda S., Kasai F., Watanabe K., Kawakami K., Ohtani A., Iemura M.,
RA   Ozawa M., Arakawa A., Hirayama N., Kawaguchi E., Tano T., Miyata S.,
RA   Satoh M., Shimizu N., Kohara A.;
RT   "Screening for 15 pathogenic viruses in human cell lines registered at
RT   the JCRB Cell Bank: characterization of in vitro human cells by viral
RT   infection.";
RL   R. Soc. Open Sci. 5:172472-172472(2018).
//